Life Science News

Late-Breaking TROPiCS-02 Study Results in Heavily Pre-Treated HR+HER2- Metastatic Breast Cancer Patients to be Featured in ASCO Press Program –

New Sub-Analysis from Kite's ZUMA-7 CAR T-cell Therapy Study in Patients Aged 65+ and Data by Tumor Burden Characteristics in Second-Line Large B-cell Lymphoma to be Presented

Diverse Hematologic Research to be Highlighted by Phase 1b Data in MDS and AML and New Real-World Outcomes by Race and Ethnicity for CAR T-cell Therapy

Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, today announced that more than 20 abstracts, including two oral presentations and four poster discussions, will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. These data highlight promising targets across diverse tumor types and blood cancers, including hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer, metastatic triple-negative breast cancer (TNBC), large B-cell lymphoma (LBCL), myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and mantle cell lymphoma (MCL).

"Gilead has built a diverse oncology pipeline guided by our strategic framework, with a focus on depth and breadth to address the greatest gaps in care for people with overlooked, underserved and difficult-to-treat cancers," said Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences. "Anchored by our Trop-2 directed antibody-drug conjugate, CAR T-cell therapies and our investigational anti-CD47 antibody, these data reinforce the potential of our transformative science across multiple cancers."

Driving Scientific Innovation in Breast Cancers with High Unmet Need

A late-breaking presentation on the TROPiCS-02 study will examine the investigational use of Gilead's antibody-drug conjugate in heavily pre-treated patients with HR+/HER2- unresectable locally advanced or metastatic breast cancer, a population with significantly limited treatment options following endocrine resistance. The final data from the landmark ASCENT study in second-line metastatic TNBC will also be presented.

Advancing an Industry-Leading CAR T-cell Therapy Portfolio

New analyses of the Phase 3 ZUMA-7 trial will highlight results in patients aged 65+, as well as data on pre-treatment tumor burden characteristics and clinical outcomes for the first and only CAR T-cell therapy approved for initial treatment of relapsed/refractory LBCL. Additional presentations include real-world outcomes by race and ethnicity for Kite's CAR T-cell therapy in LBCL and longer-term data from the ZUMA-2 and ZUMA-3 studies assessing the durability of response to Kite's CAR T-cell therapy in relapsed/refractory MCL and relapsed/refractory adult ALL, respectively.

"At Kite, our singular focus is on developing cell therapies to treat and potentially cure cancers," said Frank Neumann, MD, PhD, Kite's Global Head of Clinical Development. "Our data at ASCO span multiple types of blood cancer and stages of treatment, reinforcing how our therapies are changing the way cancer is treated."

Furthering Potential Treatment Approaches in MDS and AML

Results of our Phase 1b study evaluating an investigational anti-CD47 antibody in combination with azacitidine in high-risk MDS and in TP53-mutant AML will be presented. MDS and AML are blood cancers which have seen limited therapeutic advancements in the past decade, and Gilead data being presented at ASCO will reinforce the potential of harnessing the innate immunity of macrophages.

Summary of Presentations

Accepted abstracts at the 2022 ASCO Annual Meeting include (all times CDT):

Abstract Disposition

Abstract Title

Breast Cancer

Abstract #LBA1001 (Oral Session)

Saturday, June 4

1:27 PM

Primary Results from TROPiCS-02: A Randomized Phase 3 Study of Sacituzumab Govitecan (SG) versus Treatment of Physician's Choice (TPC) in Patients with Hormone Receptor-Positive/HER2-Negative (HR+/HER2-) Advanced Breast Cancer

Abstract #1071

Monday, June 6

8:00 AM

Sacituzumab Govitecan (SG) versus Treatment of Physician's Choice (TPC) in Patients with Previously Treated Metastatic Triple-Negative Breast Cancer (mTNBC): Final Results from the Phase 3 ASCENT Study

Abstract #1076

Monday, June 6

8:00 AM

Exposure-Response Analyses of Sacituzumab Govitecan (SG) Efficacy and Safety in Patients with Metastatic Triple-Negative Breast Cancer (mTNBC)

Abstract #1075

Monday, June 6

8:00 AM

Real-World Treatment Patterns and Outcomes among 2nd Line (2L) and 3rd Line (3L) Metastatic Triple-Negative Breast Cancer (mTNBC) Patients in England Using the Cancer Analysis System (CAS)

Myelodysplastic Syndrome

Abstract #7017 (Poster Discussion)

Saturday, June 4

1:15 PM

Magrolimab in Combination with Azacitidine for Untreated Higher-Risk Myelodysplastic Syndromes (HR-MDS): 5F9005 Phase 1b Study Results

Abstract #7054

Saturday, June 4

8:00 AM

Impact of Magrolimab Treatment in Combination with Azacitidine on Red Blood Cells in Higher-Risk Myelodysplastic Syndrome (HR-MDS) Patients

ePublication #e19062

Clinical Outcomes Associated with Azacitidine Monotherapy for Treatment-Naïve Higher-Risk Myelodysplastic Syndrome: A Systematic Literature Review and Meta-Analysis

Acute Myeloid Leukemia

Abstract #7020 (Poster Discussion)

Saturday, June 4

1:15 PM

Tolerability and Efficacy of the First-in-Class Anti-CD47 Antibody Magrolimab Combined with Azacitidine in Frontline TP53m AML Patients: Phase 1b Results

ePublication #e19020

Treatment Outcomes for Newly Diagnosed, Untreated TP53-Mutated Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis

B-cell Lymphomas

Abstract #7571 (Oral Session)

Friday, June 3

3:12 PM

Real-World Outcomes of Axicabtagene Ciloleucel (Axi-Cel) for the Treatment of Large B-cell Lymphoma (LBCL) by Race and Ethnicity

Abstract #7548

Saturday, June 4

8:00 AM

Clinical and Patient-Reported Outcomes (PROs) in a Phase 3, Randomized, Open-Label Study Evaluating Axicabtagene Ciloleucel (Axi-Cel) versus Standard-of-Care (SOC) Therapy in Elderly Patients with Relapsed/Refractory (R/R) Large B-cell Lymphoma (LBCL) (ZUMA-7)

Abstract #7565

Saturday, June 4

8:00 AM

Association of Pretreatment (Pretx) Tumor Characteristics and Clinical Outcomes Following Second-Line (2L) Axicabtagene Ciloleucel (Axi-Cel) versus Standard of Care (SOC) in Patients with Relapsed/Refractory (R/R) Large B-cell Lymphoma (LBCL)

Abstract #7567

Saturday, June 4

8:00 AM

Axicabtagene Ciloleucel (Axi-Cel) in Combination with Rituximab (Rtx) for the Treatment of Refractory Large B-cell Lymphoma (R-LBCL): Outcomes of the Phase 2 ZUMA-14 Study

Abstract #7555

Saturday, June 4

8:00 AM

Quality-Adjusted Time without Symptoms or Toxicities (Q-Twist) Analysis of ZUMA-7, a Randomized Controlled Trial of Axicabtagene Ciloleucel versus Standard of Care for Second-Line Large B-cell Lymphoma

Abstract #TPS7579

Saturday, June 4

8:00 AM

KITE-363: A Phase 1 Study of an Autologous Anti-CD19/CD20 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Relapsed/Refractory (R/R) B-cell Lymphoma (BCL)

ePublication #e19558

Patient Preferences for Second-Line Treatment Options in Diffuse Large B-cell Lymphoma: A Discrete Choice Experiment

Mantle Cell Lymphoma

Abstract #7518 (Poster Discussion)

Saturday, June 4

3:00 PM

Three-Year Follow-Up of Outcomes with KTE-X19 in Patients with Relapsed/Refractory Mantle Cell Lymphoma in ZUMA-2

Acute Lymphoblastic Leukemia

Abstract #7010 (Poster Discussion)

Saturday, June 4

1:15 PM

Two-Year Follow-Up of KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) in ZUMA-3

Non-Small Cell Lung Cancer

Abstract #TPS9149

Monday, June 6

8:00 AM

EVOKE-01: A Phase 3 Study of Sacituzumab Govitecan (SG) versus Docetaxel in Patients with Non-Small Cell Lung Cancer (NSCLC) Progressing On or After Platinum-Based Chemotherapy and Checkpoint Inhibitors

Abstract #TPS9146

Monday, June 6

8:00 AM

EVOKE-02: A Phase 2 Study of Sacituzumab Govitecan Plus Pembrolizumab with or without Platinum Chemotherapy in First-Line Metastatic Non-Small Cell Lung Cancer (NSCLC)

Advanced Solid Tumors

Abstract #2566

Sunday, June 5

8:00 AM

Phase 1b Study of GS-3583, A Novel FLT3 Agonist Fc Fusion Protein, in Patients with Advanced Solid Tumors

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

About Kite

Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, with manufacturing operations in North America and Europe. Kite's singular focus is cell therapy to treat and potentially cure cancer. As the global cell therapy leader, Kite has more approved CAR T indications to help more patients than any other company.

Forward-Looking Statements

This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the ability of Gilead and Kite to initiate, progress or complete clinical trials within currently anticipated timelines or at all, and the possibility of unfavorable results from ongoing or additional clinical studies, including those involving Tecartus, Trodelvy, Yescarta and magrolimab; the possibility that Gilead and Kite may make a strategic decision to discontinue development of these programs and, as a result, these programs may never be successfully commercialized for the indications currently under evaluation; and any assumptions underlying any of the foregoing. These and other risks, uncertainties and factors are described in detail in Gilead's Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, as filed with the U.S. Securities and Exchange Commission. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead and Kite, and Gilead and Kite assume no obligation and disclaim any intent to update any such forward-looking statements.

Gilead, the Gilead logo, Kite and the Kite logo are trademarks of Gilead Sciences, Inc., or its related companies.

For more information about Gilead, please visit the company's website at www.gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

For more information on Kite, please visit the company's website at www.kitepharma.com . Follow Kite on social media on Twitter (@KitePharma) and LinkedIn .

Jacquie Ross, Investors
investor_relations@gilead.com

Nathan Kaiser, Gilead Media
nathan.kaiser@gilead.com

Anna Padula, Kite Media
apadula@kitepharma.com

News Provided by Business Wire via QuoteMedia

GILD
abigail echo-hawk

CORRECTION: Contakt World Becomes Data Partner for Health Equity Tracker Project to Improve the Collection of De-Identified Racial & Ethnic Minority Data Using Smart Health RM, Engagency, and Future Services

Enables Contakt World mission to improve health equity and reduce disparities in the fight against Covid-19 and all diseases via award-winning SaaS platform

This document corrects and updates the final paragraph in the body of this news release. No other changes were required in this release.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
"investingnews.com"

Contakt World Becomes Data Partner for Health Equity Tracker Project to Improve the Collection of De-Identified Racial & Ethnic Minority Data Using Smart Health RM, Engagency, and Future Services

Enables Contakt World mission to improve health equity and reduce disparities in the fight against Covid-19 and all diseases via award-winning SaaS platform

  • Covid-19 has proven to be the "great revealer" of disparities in healthcare

  • Contakt World (CSE: HELP) and Satcher Health Leadership Institute, Morehouse School of Medicine executed a strategic collaboration in October 2020
  • Health Equity Tracker, supported by Google.org, Gilead Sciences (Nasdaq: GILD), Annie E. Casey Foundation, and CDC Foundation, is now operational
  • Contakt World's SaaS Platform, Smart Health RM, will help drive de-identified data to Health Equity Tracker to improve health equity and reduce disparities of care

Contakt World Technologies Corp. (CSE: HELP) (OTC: TLOOF) (FSE: B2I0) (the "Company" or "Contakt World") today announced its agreement in principle with Satcher Health Leadership Institute, Morehouse School of Medicine ("SHLI") to help collect de-identified demographic data for the Health Equity Tracker Project through Smart Health RM and other products and services provided by Contakt World like Engagency. This updates the previously announced collaboration between Contakt World and SHLI now that Health Equity Tracker is operational.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

HOOKIPA Advances HIV and HBV Vaccine Research with Gilead

HOOKIPA Pharma (NASDAQ:HOOK) announced that it has made progress in its collaboration with Gilead Sciences (NASDAQ:GILD) for arenavirus-based therapeutics intended to support cures for chronic Hepatitis B virus (HBV) and human immunodeficiency virus (HIV) infections.

As quoted in the press release:

Keep reading...Show less

Kite Announces Initial Results From a Phase 1 Study of T Cell Receptor (TCR) Cell Therapy in HPV-16-Positive Solid Tumors

Kite, a Gilead Company (Nasdaq: GILD), today announced results from an ongoing Phase 1 study conducted by the National Cancer Institute (NCI) showing that clinical responses were observed with investigational T cell receptor (TCR) cell therapy targeting human papillomavirus type 16 (HPV-16) E7 in solid tumor cancers caused by HPV. These findings were presented today in a poster session at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago (Abstract #3043).

As quoted in the press release:

Keep reading...Show less

Gilead Sciences Announces Promotion in Oncology Division

Gilead Sciences (NASDAQ:GILD) shared the promotion of Dr. Alessandro Riva to executive vice president of Oncology Therapeutics, with responsibility for Gilead’s hematology and oncology programs.
As quoted in the press release:

Dr. Riva will become a member of Gilead’s senior leadership team.
Dr. Riva joined Gilead in January 2017 as Senior Vice President, Hematology and Oncology Therapeutic Area Head. He has been instrumental in expanding Gilead’s oncology program with the recent acquisition of Kite Pharma, establishing the company as a leader in the field of cellular therapy. He has also guided the strategy and development of Gilead’s broader oncology pipeline during his tenure.

Keep reading...Show less
Boosh Gross Sales for June 2022

Boosh Gross Sales for June 2022

Boosh Plant-Based Brands Inc. (CSE: VEGI) (OTCQB: VGGIF) (FSE: 77i) ("Boosh" or the "Company") is pleased to announce that it generated gross sales revenues of CA$897,048 in the month of June 2022. Costs of goods sold was $534,030.43 for the same month.

Boosh Founder and CEO Connie Marples states, "Now that we have fully integrated Beanfields Chips into our family of brands we are seeing a dramatic increase in our sales revenues. It is exciting to be shipping large volumes of product out to stores with reorders coming in fast and furious. We are working on continuing to scale up production to meet retailers demands."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

BELLUS Health to Participate in the William Blair Biotech Focus Conference

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other cough hypersensitivity indications, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will be participating in a fireside chat at the William Blair Biotech Focus Conference.

Presentation Details:
Event: William Blair Biotech Focus Conference
Date/Time: Monday, July 11 th , 2022 at 9:00 a.m. ET
Format: Prerecorded fireside chat

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
The Gummy Project Announces Official Launch of E-Commerce Sales Channel

The Gummy Project Announces Official Launch of E-Commerce Sales Channel

  • The Gummy Project'S Watermelon Sharks and Peachy Bees are now available for pre-sale purchase at www.shopgummies.com
  • Shipping and fulfilment of online orders will commence on July 11, 2022

The Gummy Project (CSE: GUMY) (FSE: 0OS2) (OTCQB: POTVF) ("GUMY" or the "Company") is pleased to announce the official launch of its new e-commerce site at www.shopgummies.com.

"The launch of our e-commerce site is a major milestone, making our product available across Canada for the first time," said Anthony Gindin, Chief Marketing Officer at GUMY. "This really marks our official launch into the Canadian market with e-commerce being a major component in our overall sales channel strategy. The site provides a vehicle for continued growth as well as a platform to share our story and fulfil our mandate to support endangered keystone species."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Cardiol Therapeutics Reports Results of 2022 Annual General Meeting

Cardiol Therapeutics Reports Results of 2022 Annual General Meeting

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of cannabidiol as an anti-inflammatory and anti-fibrotic therapy for the treatment of cardiovascular diseases ("CVD"), announces the results from its Annual General Meeting of Shareholders (the "AGM") held virtually via live audio webcast, on June 28, 2022. Shareholders voted in favour of all management resolutions proposed in the Company's Information Circular.

Resolutions proposed and approved at the AGM were:

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
The Gummy Project Announces Another Milestone with Entry into Canadian Retail Market

The Gummy Project Announces Another Milestone with Entry into Canadian Retail Market

  • The Gummy Project'S Watermelon Sharks and Peachy Bees to be sold at Vancouver based Stong's Markets
  • Stong's are Vancouver owned full-service grocery stores that have operated in Vancouver since 1931

The Gummy Project (CSE: GUMY) (FSE: 0OS2) (OTCQB: POTVF) ("GUMY" or the "Company") is pleased to announce that as of June 29, 2022 it has partnered with Stong's to launch its Watermelon Sharks and Peachy Bees into the Canadian retail market.

"This partnership represents another great step in our ongoing sales strategy and we're extremely proud to partner with Stong's, an iconic grocery store in Vancouver," said Charlie Lamb, President and CEO of GUMY. "Following our recent partnership announcements with Flair Airlines and Bard on the Beach, the upcoming launch of our ecommerce site on June 30 2022, and our distribution partnership with Dean's Dairy and Specialty Foods, consumers will soon be able to purchase our products at locations across Canada."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Health Canada Approves OPDIVO® as Monotherapy for the Adjuvant treatment of Adults with Urothelial Carcinoma at High Risk of Recurrence after Undergoing Radical Resection of UC

First adjuvant Immunotherapy for patients at high risk of disease recurrence

Today, Bristol Myers Squibb Canada (BMS) announced Health Canada has issued a Notice of Compliance with Conditions (NOCc) for OPDIVO ® , as a monotherapy for the adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC. i OPDIVO ® is the first immuno-oncology treatment to bring benefit in the adjuvant setting of UC and represents a potential new standard of care for patients at high risk of disease recurrence. ii Unlike traditional cancer therapies that target the tumour directly, immuno-oncology activates the body's own immune system to help recognize and attack cancer cells. iii

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×